Pharmamel, the biotechnology spin-off and start-up from the prestigious University of Granada, is in the spotlight with the launch of its ambitious capital increase campaign, titled \u201cGo to BME Scaleup.\u201d This initiative marks an important moment in the company’s trajectory as it seeks to obtain the necessary resources to conduct a Phase III clinical trial in Europe and the United States for its new intravenous drug aimed at treating sepsis, one of the leading causes of hospital death. Stay updated with all the latest from BME Growth!<\/p>\n\n
Sepsis has long been a significant challenge in the field of medicine, with high mortality rates and an urgent need for more effective treatment options. Pharmamel has developed, patented, and tested a new intravenous drug that has proven to be promising in reducing mortality and hospital stay associated with sepsis. This breakthrough represents real hope for millions of patients worldwide who are battling this devastating disease. \n<\/p>\n\n
La sepsis ha sido durante mucho tiempo un desaf\u00edo importante en el campo de la medicina, con altas tasas de mortalidad y una necesidad urgente de opciones de tratamiento m\u00e1s efectivas. Pharmamel ha desarrollado, patentado y probado un nuevo f\u00e1rmaco intravenoso que ha demostrado ser prometedor en la reducci\u00f3n de la mortalidad y la estancia hospitalaria asociada con la sepsis. Este avance representa una esperanza real para millones de pacientes en todo el mundo que luchan contra esta devastadora enfermedad. \n<\/p>\n\n
The presentation of Pharmamel’s “Go to BME Scaleup” campaign is scheduled for April 24, 2024, at 5:00 PM, in the prestigious Antonio Maura auditorium of the Madrid Stock Exchange Palace. This event will bring together biotech investors, investment funds, healthcare professionals, and representatives from the pharmaceutical industry, all interested in supporting this innovative initiative and contributing to the advancement in sepsis treatment. \n<\/p>\n\n
The event will feature prominent leaders in the fields of biotechnology and finance, including Daniel Oliver, CEO of Capital Cell, the biotechnology crowdfunding platform regulated by the CNMV, as well as Jes\u00fas Gonz\u00e1lez Nieto-M\u00e1rquez, Managing Director of BME Scaleup and BME Growth. Their presence underscores the importance and potential of this capital increase campaign for Pharmamel and its sepsis treatment project. \n<\/p>\n\n
In summary, the launch of Pharmamel’s “Go to BME Scaleup” campaign marks a significant moment in its mission to bring an innovative treatment for sepsis to market. With the support of investors and industry professionals, Pharmamel is uniquely positioned to advance its Phase III clinical trial and realize its vision of providing a more effective and hopeful treatment option for patients suffering from sepsis. This is an exciting step forward in the fight against a disease that has affected so many people worldwide, and Pharmamel is leading the way towards a healthier and more promising future. \n<\/p>\n","protected":false},"excerpt":{"rendered":"
Pharmamel, the biotechnology spin-off and start-up from the prestigious University of Granada, is in the spotlight with the launch of its ambitious […]<\/p>\n","protected":false},"author":15,"featured_media":1747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1758","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-p"],"yoast_head":"\n